tbuckley/cabot-search huggingface dataset:
Pazopanib (P) or placebo in completely resected stage I NSCLC patients: Survival results of the phase II trial IFCT-0703.
Authors: Benjamin Besse, Julien Mazières, Laureen Ribassin-Majed, Fabrice Barlesi, Jaafar Bennouna, Radj Gervais, Lionel Moreau, Henri Berard, Didier Debieuvre, Oliver Molinier, Denis Moro-Sibilot, Pierre Jean Souquet, Jean-Pierre Pignon, Elodie Amour, Aljosa Celebic, Franck Morin, Bernard Milleron, Gerard Zalcman, Jean-Charles Soria
Journal: Journal of Clinical Oncology (2015)

7510 Background: P is an anti-angiogenic agent approved in metastatic renal cell carcinoma and sarcoma. We have previously reported compliance of adjuvant P (i.e. % of patients (pts) able to receive at least 3 months (m.) of P, whatever the dose) in stage I NSCLC. Compliance has already been reported (WCLC 2013) and has been found adequate at the dose 400 mg/d (69% [95%CI 50-84] (p = 0.027, compared to 38% in P 800 mg/d) vs 93% [95%CI 77-99] in placebo. Here we report survival data. Methods: In this double-blind non-comparative randomized multicenter phase II trial, 143 pts with resected stage I NSCLC (7thTNM edition) were randomized to receive placebo or P 800 mg/d during 6 m. The Fleming’s two-stage primary endpoint was compliance. After 64 pts included (interim analysis), IDMC recommended to start with P 400 mg/d because of initial insufficient compliance. A one-step Fleming design was used with the new dose. Here, we present survival data for which the intent to treat analysis was performed in 142 pts (1 consent withdrawal). Results: Between Mar 2009 and Aug 2012, 71 pts were enrolled in each arm. Most pts were male (61%) and smokers (91%), median age was 60. Pathological stage was IA in 103 pts (72%) and 16% were squamous cell carcinomas. No toxic deaths were observed. 2 pts had grade (G) 4 toxicities in P800 (fatigue in P arm, GGT in the placebo arm). Most common G3 toxicities in P800 were diarrhea (9%), hypertension (13%), and increased transaminases (16% vs. 0% in P400); in P400 gastro-intestinal disorders (16%, 6% diarrhea) and hypertension (6%). Median follow-up was 47 m. The number of events for disease free survival (DFS) is 17 in the P arm and 13 in the placebo arm: 3 yrs DFS rates were 77% [95%CI 67%-87%] and 83% [95%CI 74%-92%] respectively (Hazard Ratio (HR) = 1.3 [95%CI 0.6-2.8], p = 0.53). Among the 14 deaths, 9 occurred in the P arm and 5 in the placebo arm. All deaths were secondary to tumor recurrence but 2, related to cardiac events (1 in each arm). 5 yrs overall survival rates were 83% [95%CI 72-94] in the P arm and 94% [95%CI 88-100] in the placebo arm (HR = 1.9 [95%CI 0.6-5.5], p = 0.27, unplanned analysis). Conclusions: Although comparison of survival was unplanned in this phase II, our results do not support a phase III trial. Clinical trial information: NCT00775307.
Aptamers in the Therapeutics and Diagnostics Pipelines
Authors: Harleen Kaur, John G. Bruno, Amit Kumar, Tarun Kumar Sharma
Journal: Theranostics (2018)

Aptamers are short single-stranded DNA or RNA oligonucleotides that can selectively bind to small molecular ligands or protein targets with high affinity and specificity, by acquiring unique three-dimensional structures.Aptamers have the advantage of being highly specific, relatively small in size, non-immunogenic and can be easily stabilized by chemical modifications, thus allowing expansion of their diagnostic and therapeutic potential.Since the invention of aptamers in the early 1990s, great efforts have been made to make them clinically relevant for diseases like macular degeneration, cancer, thrombosis and inflammatory diseases.Furthermore, owing to the aforementioned advantages and unique adaptability of aptamers to point-of-care platforms, aptamer technology has created a stable niche in the field of in vitro diagnostics by enhancing the speed and accuracy of diagnoses.The aim of this review is to give an overview on aptamers, highlight the inherent therapeutic and diagnostic opportunities and challenges associated with them and present various aptamers that have reached therapeutic clinical trials, diagnostic markets or that have immediate translational potential for therapeutics and diagnostics applications.
Clinical Trials Comparing Surgical vs Nonsurgical Therapy—Reply
Authors: George Howard, Richard A. Kronmal
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Generic for Opioid Use Disorder
Authors: Rebecca Voelker
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Visual Inspection of Chromatograms Assists Interpretation of HbA1c: A Case Report
Authors: Qianrui Li, Yuling Xiao, Anoop Dinesh Shah, Sheyu Li
Journal: Diabetes Care (2018)

A 58-year-old woman presented with elevated fasting plasma glucose found in a medical check-up. She was asymptomatic, and clinical examination was normal apart from slight sclera jaundice. The 75-g oral glucose tolerance test showed fasting plasma glucose of 5.6 mmol/L and 2-h postprandial plasma glucose of 5.98 mmol/L. The HbA1c taken at the same visit was 2.0% (value unavailable in International Federation of Clinical Chemistry and Laboratory Medicine [IFCC] units) (assayed by the Tosoh G8 analyzer); on retesting, it was 3.6% (16 mmol/mol) (assayed by the Bio-Rad D-10 TM analyzer). The synchronous glycated albumin was 11.59%. Her other blood results were as follows: …
Th1 memory differentiates recombinant from live herpes zoster vaccines
Authors: Myron J. Levin, Miranda E. Kroehl, Michael J. Johnson, Andrew Hammes, Dominik Reinhold, Nancy Lang, Adriana Weinberg
Journal: Journal of Clinical Investigation (2018)

The adjuvanted varicella-zoster virus (VZV) glycoprotein E (gE) subunit herpes zoster vaccine (HZ/su) confers higher protection against HZ than the live attenuated zoster vaccine (ZV). To understand the immunologic basis for the different efficacies of the vaccines, we compared immune responses to the vaccines in adults 50 to 85 years old. gE-specific T cells were very low/undetectable before vaccination when analyzed by FluoroSpot and flow cytometry. Both ZV and HZ/su increased gE-specific responses, but at peak memory response (PMR) after vaccination (30 days after ZV or after the second dose of HZ/su), gE-specific CD4+ and CD8+ T cell responses were 10-fold or more higher in HZ/su compared with ZV recipients. Comparing the vaccines, T cell memory responses, including gE–IL-2+ and VZV–IL-2+ spot-forming cells (SFCs), were higher in HZ/su recipients and cytotoxic and effector responses were lower. At 1 year after vaccination, all gE-Th1 and VZV–IL-2+ SFCs remained higher in HZ/su compared with ZV recipients. Mediation analyses showed that IL-2+ PMR were necessary for the persistence of Th1 responses to either vaccine and VZV–IL-2+ PMR explained 73% of the total effect of HZ/su on persistence. This emphasizes the biological importance of the memory responses, which were clearly superior in HZ/su compared with ZV participants.
Exploring the margins of SERS in practical domain: An emerging diagnostic modality for modern biomedical applications
Authors: Manu M. Joseph, Nisha Narayanan, Jyothi B. Nair, Varsha Karunakaran, Adukkadan N. Ramya, Palasseri T. Sujai, Giridharan Saranya, Jayadev S. Arya, Vineeth M. Vijayan, Kaustabh Kumar Maiti
Journal: Biomaterials (2018)
Review: Postdischarge home interventions can increase or decrease falls in older adults
Authors: Calvin Hirsch
Journal: Annals of Internal Medicine (2018)

Source Citation Naseri C, Haines TP, Etherton-Beer C, et al. Reducing falls in older adults recently discharged from hospital: a systematic review and meta-analysis. Age Ageing. 2018. [Epub ahead of print]. 29584895
Teens Shift to Electronic Cigarettes
Authors: Bridget M. Kuehn
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization
Authors: Stuart J. Head, Milan Milojevic, Joost Daemen, Jung-Min Ahn, Eric Boersma, Evald H. Christiansen, Michael J. Domanski, Michael E. Farkouh, Marcus Flather, Valentin Fuster, Mark A. Hlatky, Niels R. Holm, Whady A. Hueb, Masoor Kamalesh, Young-Hak Kim, Timo Mäkikallio, Friedrich W. Mohr, Grigorios Papageorgiou, Seung-Jung Park, Alfredo E. Rodriguez, Joseph F. Sabik, Rodney H. Stables, Gregg W. Stone, Patrick W. Serruys, A. Pieter Kappetein
Journal: Journal of the American College of Cardiology (2018)
AODTU-006 Does a hospital alcohol service have a financial impact by way of reduction in length of stay and reduction in readmissions?
Authors: V Patel, K Lyons
Journal: Gut (2017)

Introduction  The scale of alcohol consumption and harmful alcohol use in Tameside is disproportionally higher, than the national average.  Method  The Hospital Alcohol Liaison Service (HALS) supports patients attending the Hospital for urgent and planned care, who are identified as dependent drinkers and those who attend as a direct result of alcohol related harm. We launched therapeutic pathways for acute alcohol withdrawal, Monitor lengths of Hospital stay, Educate all staff in Alcohol related harm, Launch protocols to ensure all patients are screened for alcohol related harm,Seamlessly refer patients to Community treatment providers, ensure access to recovery pathways within the community and Reduce Liver Harm.There was an inconsistent approach to Acute Alcohol management. We identified: variable clinical outcomes, protracted hospital stays and high re-admissions rate.The Team consists of 3 Specialist Nurses, Administrator and Gastroenterologist. The team offers a duty response to all Inpatient and Outpatient departments within the hospital,the service also operates a daily Ambulatory Detoxification clinic. The team identify patients with alcohol related harm, initiating, facilitating and evaluating safe clinical treatment pathways. The service involved all staff groups, through multi-disciplinary education programmes. The Team are responsible for delivering training throughout the Trust-sharing expertise and developing skills throughout the nursing and wider clinical community workforce. The Team coordinate safe clinical pathways - which extend past inpatient stay and involve community referral  Results  Quantitative data is collated and analysed on a quarterly basis. These are distributed throughout the Trust with recommendations for future service development. Data is sourced through patient feedback: this data reflects a strong position in respect to patient experience of both the treatment process and person centred clinic. Over 3428 patients, have been assessed, treated to date. 84.2% of patients who engaged in Detoxification via the Ambulatory Detox clinic have remained abstinent for over six months. There is a reduction in 30 day, 60 day readmissions for alcohol related primary diagnosis 38.17% and 38.66% respectively as compared with period before the HALS service.Average Lengths of Stay is reduced from 4.7 days to 1.3 days. Saving of £2.2478,728 by way of 10 112 bed days saved over 3 years (costed @ £220 a day). This has been sustained a period in excess of 3 years.  Conclusion  A HALS service can with education programs and early referal to community services, detox protocols and ambulatory protocols has a large impact on alcohol related harm, reduction in lengths of stay and readmissions  Reference  . The Lancet, Vol. 384, No. 9958, p1953–1997.  Disclosure of Interest  None Declared
Maresin 1 improves the Treg/Th17 imbalance in rheumatoid arthritis through miR-21
Authors: Shengwei Jin, Huaijun Chen, Yongsheng Li, Hao Zhong, Weiwei Sun, Jianmin Wang, Tingting Zhang, Jinglan Ma, Songfan Yan, Jiangang Zhang, Qingqing Tian, Xinyu Yang, Jianguang Wang
Journal: Annals of the Rheumatic Diseases (2018)

Objective Treg/Th17 imbalance plays an important role in rheumatoid arthritis (RA). Maresin 1 (MaR1) prompts inflammation resolution and regulates immune responses. We explored the effect of MaR1 on RA progression and investigated the correlation between MaR1 and Treg/Th17 balance. Methods Both patients with RA and healthy controls were recruited into the study. Collagen-induced arthritis (CIA) model was constructed to detect the clinical score, histopathological changes and Treg/Th17 ratio. Purified naive CD4+ T-cells were used to study the effect of MaR1 on its differentiation process and microRNA microarray studies were performed to investigate MaR1 downstream microRNAs in this process. MicroRNA transfection experiments were conducted by lentivirus to verify the mechanism of MaR1 on Treg/Th17 balance. Results Compared with controls, the MaR1 concentration was higher in the patients with inactive RA and lower in the patients with active RA. Expression of the Treg transcription factor FoxP3 was the highest in inactive RA and the lowest in active RA, while the Th17 transcription factor RORc showed a reverse trend. An inverse correlation was observed between the FoxP3/RORc ratio and Disease Activity Score 28. Intervention of MaR1 in the CIA model reduced joint inflammation and damage, and improved the imbalanced Treg/Th17 ratio. MaR1 increased Treg cells proportion while reduced Th17 cells proportion under specific differentiation conditions. Furthermore, miR-21 was verified as MaR1 downstream microRNA, which was upregulated by MaR1, modulating the Treg/Th17 balance and thus ameliorating the RA progression. Conclusions MaR1 is a therapeutic target for RA, likely operating through effects on the imbalanced Treg/Th17 ratio found in the disease.
The replicability revolution
Authors: Ulrich Schimmack
Journal: Behavioral and Brain Sciences (2018)

Abstract Psychology is in the middle of a replicability revolution. High-profile replication studies have produced a large number of replication failures. The main reason why replication studies in psychology often fail is that original studies were selected for significance. If all studies were reported, original studies would fail to produce significant results as often as replication studies. Replications would be less contentious if original results were not selected for significance.
European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation
Authors: Nicole Engel, Alicia Rovo, Manuela Badoglio, Myriam Labopin, Grzegorz W. Basak, Yves Beguin, Denis Guyotat, Per Ljungman, Arnon Nagler, Anton Schattenberg, Thomas Schroeder, Wilfried Schroyens, Johanna Tischer, Gerard Socie, Hans-Jochem Kolb, Andre Tichelli, Nina Salooja, Rafael F. Duarte
Journal: Leukemia (2018)
Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids
Authors: Xu Han, Allen Lee, Sha Huang, Jun Gao, Jason R. Spence, Chung Owyang
Journal: Gut Microbes (2018)

Disruption of intestinal barrier homeostasis is an important pathogenic factor in conditions such as irritable bowel syndrome (IBS). Lactobacillus rhamnosus GG (LGG) improves IBS symptoms through unclear mechanisms. Previous studies utilizing colorectal adenocarcinoma cell lines showed that LGG metabolites prevented interferon gamma (IFN-gamma) induced barrier damage but the model employed limited these findings. We aimed to interrogate the protective effects of LGG on epithelial barrier function using human intestinal epithelial cultures (enteroids and colonoids) as a more physiologic model. To investigate how LGG affects epithelial barrier function, we measured FITC-Dextran (FD4) flux across the epithelium as well as tight junction zonula occludens 1 (ZO-1) and occludin (OCLN) expression. Colonoids were incubated with fecal supernatants from IBS patients (IBS-FSN) and healthy controls in the presence or absence of LGG to examine changes in gut permeability. Enteroids incubated with IFN-gamma demonstrated a downregulation of OCLN and ZO-1 expression by 67% and 50%, respectively (p<0.05). This was accompanied by increased paracellular permeability as shown by leakage of FD4. Pretreatment of enteroids with LGG prevented these changes and normalized OCLN and ZO-1 to control levels. These actions were independent of its action against apoptosis. However, these protective effects were not seen with LGG cell wall extracts, LGG DNA, or denatured (boiled) LGG. Intriguingly, IBS-FSN injected into colonoids increased paracellular permeability, which was prevented by LGG. LGG, likely due to secreted proteins, protects against epithelial barrier dysfunction. Bacterial-derived factors to modulate gut barrier function may be a treatment option in disorders such as IBS.
Annals Consult Guys – A Stumper: How Much Spent for How Much Prevention?
Authors: Geno J. Merli, Howard H. Weitz
Journal: Annals of Internal Medicine (2018)

Web Exclusives17 July 2018Annals Consult Guys – A Stumper: How Much Spent for How Much Prevention?FREEGeno J. Merli, MD and Howard H. Weitz, MDGeno J. Merli, MDThomas Jefferson University, Philadelphia, Pennsylvania (G.J.M., H.H.W.)Search for more papers by this author and Howard H. Weitz, MDThomas Jefferson University, Philadelphia, Pennsylvania (G.J.M., H.H.W.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W18-0012 SectionsSupplemental MaterialAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Howard and Geno challenge us to think about what is known and what is not known about what we might assume to be well-established preventive therapy. Can your team get the right answer?For more videos from and information on Annals Consult Guys, visit go.annals.org/ConsultGuys. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Thomas Jefferson University, Philadelphia, Pennsylvania (G.J.M., H.H.W.)Disclosures: Geno J. Merli, MD, reports the following: Research grants/contracts: Bristol-Myers Squibb, Bayer. Howard H. Weitz, MD, reports that he has no financial relationships or interests to disclose.Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Darren B. Taichman, MD, PhD, Executive Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interest to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Catharine B. Stack, PhD, MS, Deputy Editor for Statistics, reports that she has stock holdings in Pfizer and Johnson & Johnson. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 July 2018Volume 169, Issue 2Page: CG1KeywordsDiagnostic techniquesDisclosurePreventive medicineResearch grantsResearch reporting guidelines ePublished: 17 July 2018 Issue Published: 17 July 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.Loading ...
Correction to: Nonacog Beta Pegol: A Review in Haemophilia B
Authors: Yahiya Y. Syed
Journal: Drugs (2018)

The article Nonacog Beta Pegol: A Review in Haemophilia B, written by Yahiya Y. Syed, was originally published Online First without open access. After publication in volume 77, issue 18, pages 2003–2012 Novo Nordisk A/S requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Novo Nordisk A/S. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.